Developer docs
API playgroundTry for free, no card

Search company profiles

Quay Pharma

Full company profile

uuid000m29u

Namestring
Quay Pharma
Websiteurl
quaypharma.com
Company typeenum
Private
Founded yearint
2002
Short descriptiontext

Quay Pharma is a privately held pharmaceutical contract development, manufacturing, and packaging organisation (CDMO), founded in 2002 and based in Deeside, operating with 101-250 employees under CEO Maireadh Pedersen and Chairman Mike Rubinstein.

Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersDeeside, Australia
HQ citystring
Deeside
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Keyword5 values
pharmaceutical contract manufacturing, contract drug development, pharmaceutical packaging services, clinical manufacturing services, formulation development
Industry4 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Contract Manufacturing
No data
Cost components5 values
Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Quay Pharma is a contract development, manufacturing and packaging organisation serving the pharmaceutical industry. It delivers outsourced services across drug development, manufacturing, and packaging to pharmaceutical clients worldwide. The company operates as a private for-profit CDMO with 101–250 employees, founded in 2002 and headquartered in Deeside.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Contract Pharmaceutical Development
No data
Peers10 records
TypeDirect peer
Description

Northern Ireland-headquartered contract development and manufacturing organisation serving global pharma with development, manufacturing, and clinical services. Highly comparable to Quay Pharma in offering breadth, mid-to-large size, and UK/Ireland regional base.

TypeDirect peer
Description

German-headquartered pharmaceutical CDMO offering development, manufacturing, and packaging of solid, semi-solid, and liquid dosage forms. Comparable to Quay Pharma as a mid-sized European contract manufacturer with similar service breadth.

TypeDirect peer
Description

Swiss-based CDMO providing API and finished drug product manufacturing services. Comparable to Quay Pharma in its integrated small-molecule development and manufacturing model.

TypeDirect peer
Description

Contract development and manufacturing organisation providing API and finished dosage form services. Comparable to Quay Pharma in offering small-molecule CDMO services to pharma clients.

5Recipharm
TypeDirect peer
Description

European CDMO offering development, manufacturing, and packaging services across small molecules and biologics. Comparable to Quay Pharma in service mix and mid-sized European footprint.

6Asymchem
TypeEmerging player
Description

China-based CDMO offering API development and manufacturing with growing finished-dose capabilities. Comparable to Quay Pharma in the API/intermediate CDMO niche though at larger scale and with a different geographic centre of gravity.

TypeDirect peer
Description

India-headquartered CDMO offering integrated development, manufacturing, and packaging services globally. Comparable to Quay Pharma across the full CDMO value chain with a similar integrated-service pitch.

TypeDirect peer
Description

European CDMO services arm of Eurofins providing contract development and manufacturing for small molecules and biologics. Comparable to Quay Pharma in service breadth and European base.

TypeBroad incumbent
Description

One of the largest global CDMOs spanning development, manufacturing, and packaging across small molecules and biologics. Overlaps with Quay Pharma on every service line but at materially greater scale and geographic reach.

TypeDirect peer
Description

Global CDMO focused on pharmaceutical and biopharmaceutical packaging, serialization, and manufacturing services. Comparable to Quay Pharma particularly across the packaging, labeling, and clinical-to-commercial supply chain segments.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Quay Pharma

Pharmaceutical Contract Manufacturingquaypharma.com

Quay Pharma is a privately held pharmaceutical contract development, manufacturing, and packaging organisation (CDMO), founded in 2002 and based in Deeside, operating with 101-250 employees under CEO Maireadh Pedersen and Chairman Mike Rubinstein.

Quay Pharma firmographics

Firmographics
Name
Quay Pharma
Website
https://quaypharma.com
Company type
Private
Founded year
2002
Headcount range
101–250 employees
Short description
Quay Pharma is a privately held pharmaceutical contract development, manufacturing, and packaging organisation (CDMO), founded in 2002 and based in Deeside, operating with 101-250 employees under CEO Maireadh Pedersen and Chairman Mike Rubinstein.
Ownership category
akta.pro rank

Quay Pharma industry classification

Industry
Product category
Pharmaceutical Contract Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Pharmaceutical contract manufacturing
  • Contract drug development
  • Pharmaceutical packaging services
  • Clinical manufacturing services
  • Formulation development

Where Quay Pharma is headquartered

Location

Headquarters

HQ city
Deeside
HQ country
Australia
HQ region
Oceania

Markets served

Quay Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D

Quay Pharma product offering

Product offering

Core offering

Quay Pharma is a contract development, manufacturing and packaging organisation serving the pharmaceutical industry. It delivers outsourced services across drug development, manufacturing, and packaging to pharmaceutical clients worldwide. The company operates as a private for-profit CDMO with 101–250 employees, founded in 2002 and headquartered in Deeside.

Differentiator

Problem solved

Functional benefit

Products and services

  • Contract Pharmaceutical Development

Companies that use Quay Pharma

Customer profile

Ideal customer profiles1 record

Quay Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Quay Pharma competitors and assessment

Company assessment

Direct peers

  • Almac Group: Northern Ireland-headquartered contract development and manufacturing organisation serving global pharma with development, manufacturing, and clinical services. Highly comparable to Quay Pharma in offering breadth, mid-to-large size, and UK/Ireland regional base.
  • Aenova: German-headquartered pharmaceutical CDMO offering development, manufacturing, and packaging of solid, semi-solid, and liquid dosage forms. Comparable to Quay Pharma as a mid-sized European contract manufacturer with similar service breadth.
  • Siegfried Holding: Swiss-based CDMO providing API and finished drug product manufacturing services. Comparable to Quay Pharma in its integrated small-molecule development and manufacturing model.
  • Cambrex: Contract development and manufacturing organisation providing API and finished dosage form services. Comparable to Quay Pharma in offering small-molecule CDMO services to pharma clients.
  • Recipharm: European CDMO offering development, manufacturing, and packaging services across small molecules and biologics. Comparable to Quay Pharma in service mix and mid-sized European footprint.
  • Piramal Pharma Solutions: India-headquartered CDMO offering integrated development, manufacturing, and packaging services globally. Comparable to Quay Pharma across the full CDMO value chain with a similar integrated-service pitch.
  • Eurofins CDMO: European CDMO services arm of Eurofins providing contract development and manufacturing for small molecules and biologics. Comparable to Quay Pharma in service breadth and European base.
  • PCI Pharma Services: Global CDMO focused on pharmaceutical and biopharmaceutical packaging, serialization, and manufacturing services. Comparable to Quay Pharma particularly across the packaging, labeling, and clinical-to-commercial supply chain segments.

Emerging players

  • Asymchem: China-based CDMO offering API development and manufacturing with growing finished-dose capabilities. Comparable to Quay Pharma in the API/intermediate CDMO niche though at larger scale and with a different geographic centre of gravity.

Broad incumbents

  • Catalent: One of the largest global CDMOs spanning development, manufacturing, and packaging across small molecules and biologics. Overlaps with Quay Pharma on every service line but at materially greater scale and geographic reach.

Market position

Customer concentration

Quay Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Quay Pharma leadership team

Management profile

Number of profiles

Profiles2 records

Quay Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Quay Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quay Pharma

What does Quay Pharma do?

Quay Pharma is a contract development, manufacturing and packaging organisation serving the pharmaceutical industry. It delivers outsourced services across drug development, manufacturing, and packaging to pharmaceutical clients worldwide. The company operates as a private for-profit CDMO with 101–250 employees, founded in 2002 and headquartered in Deeside.

When was Quay Pharma founded?

Quay Pharma was founded in 2002. It employs 101 to 250 people.

Where is Quay Pharma based?

Quay Pharma is headquartered in Deeside, Australia, in the Oceania region.

Who are Quay Pharma's main competitors?

Direct peers on record are Almac Group, Aenova, Siegfried Holding, Cambrex, Recipharm, Piramal Pharma Solutions, Eurofins CDMO and PCI Pharma Services. Asymchem is listed as an emerging player. Catalent is listed as a broad incumbent.

Does Quay Pharma have an API?

No public API is recorded for Quay Pharma.

What industry is Quay Pharma in?

Quay Pharma's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireHealthcare Testing, Inspection, and Certification Outsourcing Global Market Report 2022: Need for Increased Pharmaceutical & Medical Device Safety Drives SectorAccording to a Research and Markets report, the global healthcare testing, inspection, and certification outsourcing market is projected to reach USD 7.7 billion by 2030, expanding at a compound annual growth rate of 8.8%, driven by heightened safety standards for medical devices and pharmaceuticals, stricter government regulations, and the adoption of advanced technologies. The report notes that testing services held the largest market share at 52.3% in 2021, while the medical device segment is forecast to grow at the fastest rate of 9.0% CAGR during the period. As an example of market consolidation, SGS SA acquired Quay Pharma, a pharmaceutical R&D organization, in December 2021 to expand its biopharmaceutical analytical testing capabilities.PR NewswireGlobal Clinical Trial Packaging Market Analysis 2020-2025, Featuring Key Players Piramal Pharma Solutions, Fisher Clinical Services, Inc. and Quay PharmaResearchAndMarkets.com published a market analysis projecting the global clinical trial packaging market to grow at a CAGR of 4.41% to reach US$1.482 billion by 2025, driven by increasing clinical trials for rare diseases and stringent regulatory packaging guidelines. The North American region, particularly the US with its flourishing pharmaceutical industry and FDA requirements, is expected to hold a significant market share over the forecast period. The report profiles key industry players including Piramal Pharma Solutions, Fisher Clinical Services, Inc., and Quay Pharma.